Table 1. Baseline patient... | American Society of Hematology

Table 1.

Baseline patient characteristics

Characteristic	Azacitidine (n = 171)	Decitabine (n = 167)	P
Age, years			.95
Median	76	76
Range	59-94	60-87
Sex			.38
Male	61	56
Female	39	44
ECOG PS			.23
0-1	53	46
2-3	47	54
Secondary AML	38	37	.82
Poor-risk cytogenetics	38	34	.43
Total WBCs ≥20 000/μL	15	13	.64
BM blasts >30%	64	71	.16
TP53 mutation	11.7	11.4	>.99
Geographic location*			.049
North America (n = 75)	45	55
Europe (n = 213)	55	45
Rest of the world (n = 50)	38	62

Characteristic	Azacitidine (n = 171)	Decitabine (n = 167)	P
Age, years			.95
Median	76	76
Range	59-94	60-87
Sex			.38
Male	61	56
Female	39	44
ECOG PS			.23
0-1	53	46
2-3	47	54
Secondary AML	38	37	.82
Poor-risk cytogenetics	38	34	.43
Total WBCs ≥20 000/μL	15	13	.64
BM blasts >30%	64	71	.16
TP53 mutation	11.7	11.4	>.99
Geographic location*			.049
North America (n = 75)	45	55
Europe (n = 213)	55	45
Rest of the world (n = 50)	38	62

Values are given as percentages, unless otherwise indicated.

WBC, white blood cell.

Percentages under Geographic Location are based on the corresponding total n in each geographic location.